1.Reflection on our country's operation-signature regulation from a legal perspective
Chinese Journal of Hospital Administration 1996;0(04):-
The operation signature regulation in force in China means giving the right of signature agreeing to the operation to a third party including the patients family. This kind of practice not only goes against the principle of informed consent and relevant regulations as stipulated in the General Rules of the Civil Law of the Peoples Republic of China and the Contract Law of the Peoples Republic of China, but is also likely to cause medical disputes. For this reason, the signatory right agreeing to the operation ought to belong to the patient himself unless it is a legal matter.
2.Current Situation of Research on Treating Metabolic Syndrome from TCM Pathogenic Phlegm, Dampness, Stasis and Heat Point of View
Wenalong LI ; Yang SU ; Ronggang CUI
International Journal of Traditional Chinese Medicine 2009;31(4):376-377
Recently, many Chinese doctors have treated metabolic syndrome from pathogenic phlegm, dampness, stasis and heat, which not only meets the theory of TCM, but also has achieved good clinical effects, besides the method has been confirmed by animal experiments..
3.Influence ofFurong-Tongmai capsules on myocardial expression of LN and CollagenⅢ in diabetes mellitus rats
Lixin WANG ; Yuansong WANG ; Fengsheng TIAN ; Ronggang CUI ; Yang SU ; Xiue CHI ; Yun BIAN
International Journal of Traditional Chinese Medicine 2017;39(2):140-143
Objective To explore the the influence ofFurong-Tongmai capsules on myocardial expression of LN and CollagenⅢ in diabetes mellitus (DM) rats.Methods A total of 60 rats were randomly divided into the control group, the model group, the low-, middle- high-dosageFurong-Tongmai capsules group (n=10). The low-, middle-high-dosageFurong-Tongmai group was given 1.4, 0.7, 2.8 g/(kg body weight) Furong-Tongmai capsules. The other two groups were given the same dose of purified water. After 8 weeks treatment, the myocardial was taken to make pathology slice with SP immunohistochemistry staining. The expression of LN and CollagenⅢ were detected.Results Compared with model group, the expression of LN (0.67% ± 0.04%,0.65% ± 0.09%vs. 1.08% ± 0.13%) and CollagenⅢ (0.67% ± 0.15%, 0.69% ± 0.13%vs. 1.17% ± 0.12%) in the middle-high-dosageFurong-Tongmai groups significantly decreased (P<0.05). However, there were no statistical differences between the low-, middle- high-dosageFurong-Tongmai groups and the model group (P>0.05).Conclusions TheFurong-Tongmai capsules could inhibit the expression of LN and CollagenⅢ in DM rats.
4.Exploration on the molecular mechanism of Sanhuang Yishen Capsules for the treatment of diabetes based on network pharmacology and experimental verification
Xiaofeng MENG ; Hailong BAI ; Yun BIAN ; Aizu ZHANG ; Fengsheng TIAN ; Ronggang CUI ; Yang SU ; Juan LI
International Journal of Traditional Chinese Medicine 2024;46(10):1330-1337
Objective:To explore the material basis and potential mechanism of Sanhuang Yishen Capsules in the treatment of diabetes through network pharmacology, molecular docking and experimental verification.Methods:The active components and targets of Sanhuang Yishhen Capsules were screened using China Natural product chemical composition database and SymMap database, and the related targets of T2DM were screened by GeneCards database. The "Chinese materia medica-active component-target" network was constructed, and the intersection genes were enriched by GO and KEGG using R language. Key active components were selected for molecular docking verification with potential core targets. 60 rats were divided into normal group, model group, and Sanhuang Yishen Capsules group according to random number table method, with 15 rats in each group. In addition to the normal group, the diabetic rat model was prepared in the other groups, and the corresponding drugs were intragastric in each group for 8 weeks. The levels of fasting blood glucose (FBG), fasting insulin (FINS) and insulin resistance index (HOMA-IR) were measured by radioimmunoassay. Western blotting was used to detect protein expressions of epidermal growth factor receptor (EGFR), epidermal growth factor (EGF), Akt serine/threonine kinase 1 (AKT1), recombinant tumor protein p53 (TP53), and recombinant caspase 3 (CASP3).Results:A total of 160 active components and 298 targets of Sanhuang Yishen Capsules, 2194 targets related to T2DM, and 166 intersection targets were obtained. GO and KEGG analyzed a series of biological reaction processes mainly involved in signal transduction, oxidative stress, apoptosis, etc., and mainly involved in the regulation of P13K/Akt, P53, CASP3 and other targets. The results of molecular docking showed that the main active components obtained by screening had strong binding with the target. Compared with model group, FBG, FINS, HOMA-IR, TP53 and CASP3 in Sanhuang Yishen Capsules group decreased ( P<0.05), EGFR, EGF and Akt1 proteins increased ( P<0.05). Conclusion:The mechanism of Sanhuang Yishen Capsules for the treatment of may be related to the regulation of EGF/EGFR/P13K/Akt signaling pathway, TP53 signaling pathway, CASP3 signaling pathway, PPARG signaling pathway, ESR1 signaling pathway, PTGS2 signaling pathway, CAT signaling pathway and CTNNB1 signaling pathway.